- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Eli Lilly Inks USD 5.9 Billion Cancer Research and Licensing Deal With Stipple Bio

Bengaluru: Drugmaker Eli Lilly has signed an oncology research collaboration and licensing agreement worth up to USD 5.9 billion with Stipple Bio, the privately held biotech firm said on Monday.
The deal gives Lilly access to Stipple Bio's technology, which is designed to identify molecules that can distinguish cancer cells from healthy tissue, potentially enabling Lilly to develop therapies that are more effective and cause fewer side effects.
Stipple Bio will receive an upfront payment, an equity investment from Lilly and aggregate payments up to $5.9 billion in research, development and commercial milestone payments, as well as tiered royalties on product sales if any therapies resulting from the collaboration reach the market, the biotech firm said.
The companies did not disclose the size of the upfront payment or Lilly's equity investment.
Lilly declined to comment beyond the company's announcement of the deal.
The partnership adds to Lilly's efforts to expand its oncology pipeline as the drugmaker seeks to grow beyond its blockbuster diabetes and obesity medicines.
Lilly's oncology portfolio includes breast cancer drug Verzenio and blood cancer drug Jaypirca. The company is also developing a range of experimental cancer treatments, including targeted therapies, antibody-drug conjugates and immuno-oncology medicines.
Stipple Bio, based in Cambridge, Massachusetts, is developing its own pipeline of precision oncology therapies. Its lead candidate, antibody-drug conjugate STP-100, is expected to enter an early-stage trial in early 2027 in solid tumors, including pancreatic cancer.
Sheeba Farhat Joined Medical Dialogues in 2018 to report on the latest Education news. A Graduate of the University of Delhi, she specializes in covering stories related to Medical Education updates. For inquiries or further information, you can reach her at editorial@medicaldialogues.in.

